secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-099424
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics FY2025 net loss narrows to $99.5M; cash $106.4M; IND cleared for PRT12396
--------------------------------------------------------------------------------

- Net loss of $99.5M ($1.29/share) improved from $127.2M ($1.68/share) in 2024.
- Cash, equivalents and marketable securities $106.4M as of Dec 31, 2025; runway into Q2 2027.
- FDA cleared IND for PRT12396 (mutant-selective JAK2V617F inhibitor); Phase 1 start expected Q2 2026.
- KAT6A degrader PRT13722 IND filing planned mid-2026; Phase 1 initiation in H2 2026.
- Exclusive option agreement with Incyte for JAK2 program (Nov 2025); DAC collaboration with AbCellera expanded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/0001193125-26-099424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/prld-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-099424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer